The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer

Published:2019-01 Issue: Volume:13 Page:117955491983392
ISSN:1179-5549
Container-title:Clinical Medicine Insights: Oncology
language:en
Short-container-title:Clin Med Insights Oncol

Author:

El-Amm Joelle¹,Aragon-Ching Jeanny B²^ORCID

Affiliation:

1. Hematology and Oncology, Lebanese American University, Beirut, Lebanon

2. Genitourinary (GU) Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA

Abstract

Non-metastatic castration-resistant prostate cancer (nmCRPC) is a heterogeneous disease with variable potential in developing into overt metastases. It is an area of increased unmet need in advanced prostate cancer and for which there had been no great treatments until recent US Food and Drug Administration (FDA) approval of 2 novel anti-androgens apalutamide and enzalutamide, which were both approved given benefit in metastasis-free survival. Early data on the use of darolutamide, another novel anti-androgen, are also explored. This review discusses the pivotal trials that led to the approval of apalutamide and enzalutamide in the nmCRPC setting and discusses the key promises and challenges with the use of these agents.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1179554919833927

Reference33 articles.

1. Cancer statistics, 2018

2. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model

3. A retrospective study of the time to clinical endpoints for advanced prostate cancer

4. Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate

5. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice;Frontiers in Oncology;2024-01-23

2. Longitudinal change in castration-resistant prostate cancer biomarker AST/ALT ratio reflects tumor progression;Scientific Reports;2023-09-15

3. siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway;Future Oncology;2023-09

4. Crafting a Personalized Prognostic Model for Malignant Prostate Cancer Patients Using Risk Gene Signatures Discovered through TCGA-PRAD Mining, Machine Learning, and Single-Cell RNA-Sequencing;Diagnostics;2023-06-07

5. Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review;Frontiers in Endocrinology;2023-04-11